China’s pharmaceutical manufacturing areas began recovering from coronavirus-related travel restrictions in mid-February, with production back up to half the normal rate, says US Pharmacopeia CEO Ron Piervincenzi.
The USP could detect that by reviewing Chinese sales of its physical reference standards.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?